ijms-logo

Journal Browser

Journal Browser

Special Issue "Ephrin Receptors and Cancer"

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 31 October 2021.

Special Issue Editor

Prof. Dr. Stamatios E. Theocharis
E-Mail Website
Guest Editor
First Department of Pathology, Medical School, University of Athens, Athens, Greece
Interests: apoptosis; metabolism; cytopathology; pathology; molecular pathology; immunohistochemistry
Special Issues and Collections in MDPI journals

Special Issue Information

The family of receptor tyrosine kinases (RTKs), ephrin receptors (EPHs), comprises 14 cell-bound members divided into two classes, A and B, based on their sequence similarity and binding affinity to their ligands, ephrins. In a similar manner, ephrins are also cell-bound proteins and include ephrin-A and ephrin-B classes. Nine class A EPHs (EPHA1-EPHA8, EPHA10) and five class B EPHs (EPHB1-EPHB4, EPHB6) preferentially bind five ephrin-A and three ephrin-B classes. The EPH/ephrin system is involved into key regulatory processes of human physiology: it highlights axon guidance and synaptic plasticity in the nervous system, as well as angiogenesis, vascular remodeling, and homeostasis of various tissues. In addition, this cell–cell communication system is implicated in several pathologic processes, including neurodegenerative disorders, viral infections, and cancer. Indeed, its deregulation affects tumor growth, progression, metastasis, and neovascularization by disrupting critical signaling transduction pathways. EPHs’ and ephrins’ aberrant expression characterizes not only the tumor cells but also the tumor microenvironment, where endothelial cells have mostly been investigated; this makes the EPH/ephrin system an appealing candidate for targeted intervention. EPHs’ upregulation in the pathogenesis of malignant transformation has been reported, suggesting their use as potential biomarkers and drug targets for various cancer types.

Prof. Stamatios E. Theocharis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ephrin receptors
  • ephrins
  • cancer
  • pathogenesis
  • biomarkers
  • treatment

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
The Clinical Impact of the EPH/Ephrin System in Cancer: Unwinding the Thread
Int. J. Mol. Sci. 2021, 22(16), 8412; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22168412 - 05 Aug 2021
Viewed by 335
Abstract
Erythropoietin-producing human hepatocellular receptors (EPHs) compose the largest known subfamily of receptor tyrosine kinases (RTKs). They bind and interact with the EPH family receptor interacting proteins (ephrins). EPHs/ephrins are implicated in a variety of physiological processes, as well as in cancer pathogenesis. With [...] Read more.
Erythropoietin-producing human hepatocellular receptors (EPHs) compose the largest known subfamily of receptor tyrosine kinases (RTKs). They bind and interact with the EPH family receptor interacting proteins (ephrins). EPHs/ephrins are implicated in a variety of physiological processes, as well as in cancer pathogenesis. With neoplastic disease remaining a leading cause of death world-wide, the development of novel biomarkers aiding in the field of diagnosis, prognosis, and disease monitoring is of utmost importance. A multitude of studies have proven the association between the expression of members of the EPH/ephrin system and various clinicopathological parameters, including disease stage, tumor histologic grade, and patients’ overall survival. Besides their utilization in timely disease detection and assessment of outcome, EPHs/ephrins could also represent possible novel therapeutic targets. The aim of the current review of the literature was to present the existing data regarding the association between EPH/ephrin system expression and the clinical characteristics of malignant tumors. Full article
(This article belongs to the Special Issue Ephrin Receptors and Cancer)
Show Figures

Figure 1

Back to TopTop